Giannarelli R, Coppelli A, Sartini M S, Del Chiaro M, Vistoli F, Rizzo G, Barsotti M, Del Prato S, Mosca F, Boggi U, Marchetti P
Department of Endocrinology and Metabolism, Metabolic Unit, University of Pisa, Pisa, Italy.
Diabetologia. 2006 Dec;49(12):2977-82. doi: 10.1007/s00125-006-0463-5. Epub 2006 Oct 5.
AIMS/HYPOTHESIS: The effects of successful pancreas transplant alone (PTA) on chronic complications of diabetes, in particular diabetic retinopathy, remain disputed. We prospectively studied the course of diabetic retinopathy in PTA recipients and in non-transplanted (non-PTA) type 1 diabetic patients.
The PTA and non-PTA groups consisted respectively of 33 (follow-up: 30 +/- 11 months) and 35 patients (follow-up: 28 +/- 10 months). Best corrected visual acuity, slit lamp examination, intraocular pressure measurement, ophthalmoscopy, retinal photographs, and in selected cases angiography were performed. Diabetic retinopathy and its improvement/deterioration were assessed according to criteria proposed by the Eurodiab Study.
At baseline, 9% of PTA and 6% of non-PTA patients had no diabetic retinopathy, 24 and 29% had non-proliferative diabetic retinopathy (NPDR), whereas 67 and 66% had laser-treated and/or proliferative diabetic retinopathy (LT/PDR), respectively. No new case of diabetic retinopathy occurred in either group during follow-up. In the NPDR PTA group, 50% of patients improved by one grading, and 50% showed no change. In the LT/PDR PTA, stabilisation was observed in 86% of cases, whereas worsening of retinopathy occurred in 14% of patients. In the NPDR non-PTA group, diabetic retinopathy improved in 20% of patients, remained unchanged in 10%, and worsened in the remaining 70%. In the LT/PDR non-PTA group, retinopathy did not change in 43% and deteriorated in 57% of patients. Overall, the percentage of patients with improved or stabilised diabetic retinopathy was significantly higher in the PTA group. No differences were found between the two groups with regard to cataract lesions and intraocular pressure values.
CONCLUSIONS/INTERPRETATION: Despite a relatively short follow-up, our study shows that successful PTA can positively affect the course of diabetic retinopathy.
目的/假设:单纯成功的胰腺移植(PTA)对糖尿病慢性并发症,尤其是糖尿病视网膜病变的影响仍存在争议。我们前瞻性地研究了PTA受者和未移植(非PTA)的1型糖尿病患者糖尿病视网膜病变的病程。
PTA组和非PTA组分别由33例(随访时间:30±11个月)和35例患者(随访时间:28±10个月)组成。进行了最佳矫正视力、裂隙灯检查、眼压测量、检眼镜检查、视网膜照相,在选定病例中还进行了血管造影。根据欧洲糖尿病研究提出的标准评估糖尿病视网膜病变及其改善/恶化情况。
基线时,9%的PTA患者和6%的非PTA患者无糖尿病视网膜病变,24%和29%患有非增殖性糖尿病视网膜病变(NPDR),而分别有67%和66%患有激光治疗和/或增殖性糖尿病视网膜病变(LT/PDR)。随访期间两组均未出现新的糖尿病视网膜病变病例。在NPDR PTA组中,50%的患者病情改善一级,50%无变化。在LT/PDR PTA组中,86%的病例病情稳定,14%的患者视网膜病变恶化。在NPDR非PTA组中,20%的患者糖尿病视网膜病变改善,10%保持不变,其余70%恶化。在LT/PDR非PTA组中,43%的患者视网膜病变无变化,57%恶化。总体而言,PTA组糖尿病视网膜病变改善或稳定的患者百分比显著更高。两组在白内障病变和眼压值方面未发现差异。
结论/解读:尽管随访时间相对较短,但我们的研究表明成功的PTA可对糖尿病视网膜病变的病程产生积极影响。